U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H27N5O5
Molecular Weight 477.5124
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AVN-944

SMILES

CC[C@H](CC#N)OC(=O)N[C@@H](C)C1=CC=CC(NC(=O)NC2=CC(OC)=C(C=C2)C3=CN=CO3)=C1

InChI

InChIKey=GYCPCOJTCINIFZ-OXJNMPFZSA-N
InChI=1S/C25H27N5O5/c1-4-20(10-11-26)35-25(32)28-16(2)17-6-5-7-18(12-17)29-24(31)30-19-8-9-21(22(13-19)33-3)23-14-27-15-34-23/h5-9,12-16,20H,4,10H2,1-3H3,(H,28,32)(H2,29,30,31)/t16-,20+/m0/s1

HIDE SMILES / InChI
AVN-944 is an IMPDH (inosine 5-monophosphate dehydrogenase) inhibitor which is now being tested in phase I of clinical trials for the treatment of hematologic malignancies and solid tumors and in phase II for pancreatic cancer (in combination with gemcitabine). The drug showed good inhibition of IMPDH isoforms I and II with Ki=6-10 nM.

Originator

Curator's Comment: Licensed by Avalon Pharmaceuticals.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5418 ng/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AVN-944 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
14540 ng × h/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AVN-944 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.56 h
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AVN-944 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
250 mg single, oral
Highest studied dose
Dose: 250 mg
Route: oral
Route: single
Dose: 250 mg
Sources: Page: p.35
healthy
n = 4
Health Status: healthy
Sex: M
Food Status: FASTED
Population Size: 4
Sources: Page: p.35
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Antiproliferative effects of AVN944, a novel inosine 5-monophosphate dehydrogenase inhibitor, in prostate cancer cells.
2008 Nov 15
Gateways to clinical trials.
2009 Mar

Sample Use Guides

Pancreatic Cancer: patients took 150, 200, 250, 300, or 400 mg q12h. Advanced Stage Solid Tumors: 150 mg twice per day escalating to 750 mg twice per day.
Route of Administration: Oral
CCRF-CEM, K562, and Raji cells were plated in 0.5 ml aliquots of growth medium into 48-well plates at 2×10(4) cells per well and then incubated with various concentrations of AVN-944 (1-10 uM). In cell proliferation the IC50s ranged from 0.13 to 0.16 uM for AVN-944.
Name Type Language
AVN-944
Common Name English
AVN 944
Code English
AVN944
Code English
AVN 944 [WHO-DD]
Common Name English
CARBAMIC ACID, N-((1S)-1-(3-((((3-METHOXY-4-(5-OXAZOLYL)PHENYL)AMINO)CARBONYL)AMINO)PHENYL)ETHYL)-, (1R)-1-(CYANOMETHYL)PROPYL ESTER
Common Name English
CARBAMIC ACID, ((1S)-1-(3-((((3-METHOXY-4-(5-OXAZOLYL)PHENYL)AMINO)CARBONYL)AMINO)PHENYL)ETHYL)-, (1R)-1-(CYANOMETHYL)PROPYL ESTER
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C2087
Created by admin on Fri Dec 15 15:55:40 GMT 2023 , Edited by admin on Fri Dec 15 15:55:40 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C49181
Created by admin on Fri Dec 15 15:55:40 GMT 2023 , Edited by admin on Fri Dec 15 15:55:40 GMT 2023
PRIMARY
FDA UNII
I3NPL1V48Q
Created by admin on Fri Dec 15 15:55:40 GMT 2023 , Edited by admin on Fri Dec 15 15:55:40 GMT 2023
PRIMARY
PUBCHEM
9918559
Created by admin on Fri Dec 15 15:55:40 GMT 2023 , Edited by admin on Fri Dec 15 15:55:40 GMT 2023
PRIMARY
CAS
297730-17-7
Created by admin on Fri Dec 15 15:55:40 GMT 2023 , Edited by admin on Fri Dec 15 15:55:40 GMT 2023
PRIMARY
EPA CompTox
DTXSID80183921
Created by admin on Fri Dec 15 15:55:40 GMT 2023 , Edited by admin on Fri Dec 15 15:55:40 GMT 2023
PRIMARY
DRUG BANK
DB05500
Created by admin on Fri Dec 15 15:55:40 GMT 2023 , Edited by admin on Fri Dec 15 15:55:40 GMT 2023
PRIMARY